Development of mTORC1 specific agents for evaluation of HER2 targeted therapy using PET

被引：0
|
作者：
Wichmann, Christian W. [1 ,2 ]
Ackermann, Uwe [2 ,3 ]
Parslow, Adam C. [3 ,4 ]
Rigopoulos, Angela [3 ]
Scott, Andrew M. [3 ,4 ]
White, Jonathan M. [1 ]
机构：
[1] Univ Melbourne, Sch Chem, Bio21 Inst, Parkville, Vic, Australia
[2] Austin Hlth, Ctr PET, Heidelberg, Vic, Australia
[3] Olivia Newton John Canc Res Inst, Tumour Targeting Lab, Heidelberg, Vic, Australia
[4] La Trobe Univ, Sch Canc Med, Bundoora, Vic, Australia
来源：
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2017年 / 60卷
基金：
澳大利亚国家健康与医学研究理事会;
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
P 333
引用
收藏
页码：S506 / S506
页数：1
相关论文
共 50 条
  • [21] Association between HER2 positivity by HER2/CEP17 ratio and response to neoadjuvant HER2 targeted therapy.
    Rappazzo, Katherine Cynthia
    Chen, Heidi
    Ballinger, Tarah Jean
    Abramson, Vandana Gupta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] HER2 Expression Correlates with HER2 Amplification in Salivary Duct Carcinoma: Using a Novel Scoring System to Determine Targeted Therapy
    Keeney, M. G.
    Visscher, D. D.
    Rivera, M.
    Wismayer, D. J. Schembri
    Lewis, J. E.
    Greipp, P. T.
    Price, K. A.
    Garcia, J. J.
    MODERN PATHOLOGY, 2014, 27 : 321A - 321A
  • [23] HER2 Expression Correlates with HER2 Amplification in Salivary Duct Carcinoma: Using a Novel Scoring System to Determine Targeted Therapy
    Keeney, M. G.
    Visscher, D. D.
    Rivera, M.
    Wismayer, D. J. Schembri
    Lewis, J. E.
    Greipp, P. T.
    Price, K. A.
    Garcia, J. J.
    LABORATORY INVESTIGATION, 2014, 94 : 321A - 321A
  • [24] SUPR peptides as novel targeted molecular imaging agents for Her2
    Kelderhouse, Lindsay
    Hardy, Amanda
    Takahashi, Terry T.
    Ornelas, Argentina
    Gammon, Seth
    Howell, Shannon
    Yang, Peiying
    Wang, Pin
    Roberts, Richard W.
    Fiacco, Steve
    Millward, Steven W.
    CANCER RESEARCH, 2015, 75
  • [25] Recent advances in the HER2 targeted therapy of gastric cancer
    Matsuoka, Tasuku
    Yashiro, Masakazu
    WORLD JOURNAL OF CLINICAL CASES, 2015, 3 (01) : 42 - 51
  • [26] HER2 targeted therapy: Determinants of response and mechanisms of resistance
    Schiff, R.
    Veeraraghavan, J.
    De Angelis, C.
    Osborne, C.
    Rimawi, M. F.
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Targeted therapy for HER2 driven colorectal cancer.
    Ross, Jeffrey S.
    Ali, Siraj Mahamed
    Elvin, Julia Andrea
    Schrock, Alexa Betzig
    Suh, James
    Vergilio, Jo-Anne
    Ramkissoon, Shakti
    Severson, Eric Allan
    Daniel, Sugganth
    Fabrizio, David
    Frampton, Garrett Michael
    Miller, Vincent A.
    Stephens, Philip J.
    Gay, Laurie M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Acquired resistance to HER2 targeted therapy: A common mechanism
    Christenson, Jessica
    Kane, Susan E.
    CANCER RESEARCH, 2012, 72
  • [29] The role of HER2 in cancer therapy and targeted drug delivery
    Tai, Wanyi
    Mahato, Rubi
    Cheng, Kun
    JOURNAL OF CONTROLLED RELEASE, 2010, 146 (03) : 264 - 275
  • [30] Recent advances in the HER2 targeted therapy of gastric cancer
    Tasuku Matsuoka
    Masakazu Yashiro
    World Journal of Clinical Cases, 2015, (01) : 42 - 51
12345